A Deep Learning Algorithm Platform to Predict Autism Diagnosis and Subtypes by Integrating Clinical, Cognitive, Imaging, Gut Microbiome, and Metabolome Data

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY

This is the first human study on ASD microbiome with robust methodologies: prospective and sibling designs, metagenomics profiles, establishing an ASD multi-dimensional databank (clinic, behavior, neurocognition, brain imaging, metabolomics, and microbiome) collected using the same methodology and genetic biology simultaneously, and developing a deep learning platform for ASD diagnosis and prevention. With the accomplishment of this project, we anticipate establishing a web application for clinical and academic use. Our findings will further advance the knowledge in the pathogenetic mechanisms of ASD to enhance early detection, diagnosis, and treatment, subsequently contributing to precision medicine.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 4
Maximum Age: 25
Healthy Volunteers: f
View:

• ASD participants are (1) they have a clinical diagnosis of ASD defined by the DSM-5 criteria,1 made by board-certificated child psychiatrists and confirmed by the ADI-R/ADOS; (2) their ages range from 4 to 25; (3) both parents are Han Chinese; (4) they and their parents cooperate with all the assessments and stool and blood collection.

Locations
Other Locations
Taiwan
National Taiwan Univeristy Hospital
RECRUITING
Taipei
Time Frame
Start Date: 2020-05-01
Estimated Completion Date: 2024-04
Participants
Target number of participants: 420
Treatments
ASD group
240 ASD patients (aged 4-25 years)
Unaffected siblings of ASD
60-100 unaffected siblings of ASD probands
TD group
120 age-, and sex matched TDC from the same geographic areas of the ASD group via referral by teachers, or advertisement at college or community.
Related Therapeutic Areas
Sponsors
Leads: National Taiwan University Hospital

This content was sourced from clinicaltrials.gov